Lymphatech, Inc. appears in FDA device records at an Atlanta, Georgia address, with Mike Weiler listed as applicant contact on the K261628 record. The company’s own published documentation describes intelligent software for imaging, measurement and documentation of lymphedema and other swelling diseases, and states that its founding team came from lymphatic health and lymphedema research at Georgia Tech. The product identity that recurs across the regulatory and company material is the LymphaTech Mobile 3D Measuring Tool, a mobile 3D measurement system. [1][2][3][9]
Documented 510(k) submissions
FDA records show K251255 for the LymphaTech Mobile 3D Measuring Tool, dated April 21, 2025 and received in April 2025, with a July 22, 2025 letter addressed to Lymphatech, Inc. care of Grace Powers of Powers Regulatory Consulting. That letter lists regulation number 21 CFR 878.4160, Surgical Camera And Accessories, Class I, product code SFG, and names the WoundVision Scout as predicate device. A separate FDA record for K261628 lists the same device name, received May 15, 2026 and decided October 28, 2026 as substantially equivalent under product code OBH, regulation 870.2770, device class 2, with a Traditional clearance type and a Summary statement. [1][4][5]
The two filings sit in different classification categories, which is visible in the FDA data rather than inferred: K251255 is recorded under a Class I surgical camera regulation, while K261628 is recorded under the extremity lymphedema extracellular fluid monitor classification with a Cardiovascular advisory committee. The K261628 record also shows a review advisory committee of GU alongside the Cardiovascular advisory committee description. [1][4]
Measurement technology as described by the manufacturer
LymphaTech’s published site describes mobile 3D imaging that captures limb geometry for volume and circumference measurement in less than 60 seconds, with automated reporting that can be printed or exported and attached to patient records, and with data synchronization across multiple facilities. The company states that the process is validated by published research and captures hundreds of thousands of data points; those are company statements, not independently verified figures. A separate page describes partnerships with compression garment manufacturers and fitters to digitize measurement and ordering, with a connection to online ordering ecommerce platforms. [3][6][7]
The K251255 summary describes non-clinical bench performance testing that included linear diameter and length accuracy testing, circumference and surface area testing, volume accuracy testing compared with water displacement and perometry, and inter-operator variability assessment. The same summary states the subject device was found substantially equivalent to the predicate device based on similar indication for use, similar technologies and performance data. [4]
Applicant identity and corporate claims
The FDA applicant name is Lymphatech, Inc., and the filing address on the K261628 record is 101 Nerem St. NW, Suite 1000, Atlanta, GA 30313. That is a filing address in the FDA record and is not treated here as a verified headquarters. The company’s About page describes a founding team of researchers from Georgia Tech and a mission centered on lymphedema and other swelling diseases, and states an estimate that lymphedema affects 20 million people; the estimate is the company’s own published statement. No parent company, brand owner or corporate ownership structure is verified in the available records. [1][2][9]
What the filing record does and does not show
The linked collection contains one 510(k) record in the record sample, K261628, decided SESE, and the collection decision count is also one SESE. These counts describe the filings retrieved as of the snapshot date and are not measures of sales, total portfolio size or safety performance. The K251255 material appears in the numbered sources as an FDA letter and premarket notification page, and its decision code is not stated in the retrieved text. Commercial availability, customer names, pricing and post-market performance are not established by these records. [1][4][5]

